Understand the source comparison
Best PE-22-28 Dosage for Neurogenesis: Protocol Comparison
1mg/kg daily 12–15% ~40% MC4R Once daily subcutaneous Minimal effect on dentate gyrus proliferation markers; subtherapeutic for most neurogenic endpoints Too low. Insufficient receptor engagement to sustain CREB phosphorylation across 24-hour intervals 5mg/kg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 1mg/kg daily
- 12–15%
- ~40% MC4R
- Once daily subcutaneous
- Minimal effect on dentate gyrus proliferation markers; subtherapeutic for most neurogenic endpoints
- Too low. Insufficient receptor engagement to sustain CREB phosphorylation across 24-hour intervals
- 5mg/kg daily
- 30–35%
- ~70% MC4R
- Optimal balance; requires strict cold-chain storage and daily adherence
- This is the sweet spot. Maximal neurogenic response without HPA axis suppression or off-target MC3R effects
- 10mg/kg daily
- 32–37%
- ~78% MC4R
- Marginal BDNF gain vs 5mg/kg; increased risk of appetite suppression via MC3R binding
- Approaching the ceiling. Extra peptide doesn't deliver proportional benefit and raises safety concerns
- 15–20mg/kg daily
- 28–33%
- ~80% MC4R
- BDNF gains plateau or decline; adrenal markers (corticosterone) show suppression at 20mg/kg
- Exceeds the dose-response curve optimum. Negative feedback mechanisms reduce net neurogenic effect
- 5mg/kg every 48h
- 18–22%
- Variable (peaks ~70%, troughs ~30%)
- Every other day subcutaneous
- Allows receptor resensitization but creates subtherapeutic windows; inconsistent CREB activity
- Intermittent dosing underperforms daily protocols. Neurogenesis requires sustained signaling, not pulsatile stimulation